Title:
CD37-SPECIFIC CHIMERIC ANTIGEN RECEPTOR
Document Type and Number:
WIPO Patent Application WO/2020/004337
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing: a chimeric antigen receptor that has improved safety and is suitable for clinical applications; and the use of the chimeric antigen receptor. Disclosed is a CD37-specific chimeric antigen receptor having an antigen recognition level that is controlled by adjustment of a spacer domain thereof.
Inventors:
TERAKURA SEITARO (JP)
KIYOI HITOSHI (JP)
OKUNO SHINGO (JP)
KIYOI HITOSHI (JP)
OKUNO SHINGO (JP)
Application Number:
PCT/JP2019/024974
Publication Date:
January 02, 2020
Filing Date:
June 24, 2019
Export Citation:
Assignee:
UNIV NAGOYA NAT UNIV CORP (JP)
International Classes:
C07K16/46; A61K35/17; A61P35/00; A61P35/02; C07K16/28; C07K19/00; C12N5/0783; C12N15/13; C12N15/62; C12N15/63; C12Q1/02
Domestic Patent References:
| WO2017180993A1 | 2017-10-19 | |||
| WO2017149515A1 | 2017-09-08 | |||
| WO2017008019A1 | 2017-01-12 | |||
| WO2017062628A1 | 2017-04-13 | |||
| WO2016172703A2 | 2016-10-27 | |||
| WO2016176651A2 | 2016-11-03 | |||
| WO2018132506A1 | 2018-07-19 |
Foreign References:
| JP2010535483A | 2010-11-25 | |||
| US20110158995A1 | 2011-06-30 | |||
| JP2009502171A | 2009-01-29 |
Other References:
HICKS, S. W. ET AL.: "The antitumor activity of IMGN529, a CD 37-Targeting antibody-drug conjugate, is potentiated by rituximab in non-hodgkin lymphoma models", NEOPLASIA, vol. 19, no. 9, September 2017 (2017-09-01), pages 661 - 671, XP055611917
TERAKURA, SEITARO: "CAR-T cell therapy in combination with allogeneic stem cell transplantation", JOURNAL OF HEMATOPOIETIC CELL TRANSPLANTATION, vol. 6, no. 1, 2017, pages 1 - 7, XP055668167
TERAKURA, SEITARO: "CAR-T cell therapy in combination with allogeneic stem cell transplantation", JOURNAL OF HEMATOPOIETIC CELL TRANSPLANTATION, vol. 6, no. 1, 2017, pages 1 - 7, XP055668167
Attorney, Agent or Firm:
HAGINO Mikiharu (JP)
Download PDF: